GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

Paris, France, November 30, 2021, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided connection details for the webcast it will host with Dr. Sean P. Donahue, MD, PhD, of Vanderbilt University on outcomes among six Leber Hereditary Optic Neuropathy (LHON) patients treated bilaterally with LUMEVOQ^® under an FDA-approved compassionate use protocol.

Dr. Donahue presented his findings at the 2021 Annual Meeting of the American Academy of Ophthalmology (AAO), held in New Orleans, Louisiana, USA, from November 12-15.

The clinical data of the patients, who had not qualified for the REFLECT Phase III trial of LUMEVOQ^® because of age limitations or because enrollment had closed, indicated that bilateral intravitreal injection of the gene therapy in these adolescents and young adults resulted in “a substantial improvement in visual function” and preservation of retinal anatomy, while being associated with good tolerability of the drug. Dr. Donahue, the Coleman Professor and Vice Chair for Clinical Affairs, and Chief of the Pediatric Ophthalmology Department of the Vanderbilt Children’s Hospital in Nashville, TN, further noted that the outcomes were “not consistent with the published natural history of the 11778 [ND4] mutation”.

Thursday, December 2, 2021 (KOL Call)

8:00 – 9:00 am EST / 2:00 – 3:00 pm CET

Live webcast in English: https://bit.ly/31geZ2k

Simultaneous French translation: https://bit.ly/3lidNTf

Following his presentation, Dr. Donahue will be available for questions. The webcast will be conducted in English, with a simultaneous French translation. For those unable to attend the live broadcast, a recording will be accessible using the same links.